Novartis CEO Vas Narasimhan On The Price Of Gene Therapies: 'It's A Challenge We Have To Solve'

In May Novartis announced that it had acquired the gene therapy pioneer AveXis in a $8.7 billion deal, but according to the the Swiss drug giant CEO Vas Narasimhan, he wishes he could have bought the company much earlier.